Type II phosphoinositide 4‐kinase (PI4KII) is reported to interact with CD81, remodel actin cytoskeleton and inhibit human hepatocellular carcinoma (HCC) cell motility [21]. Here, CD81 is linked to hepatocellular carcinoma.